Bio Medica Laboratories Lists at ₹111.20, Down 23.99%

Bio Medica Laboratories Ltd, incorporated in August 2015 as a manufacturer of pharmaceutical parenteral formulations specialising in generic injectable drugs including liquid injections and dry-powder injectables for human and veterinary healthcare operating through B2B contract manufacturing model whereby it manufactures formulations based on customer specifications while client companies market products under their own brand names, made a disastrous debut on NSE SME on Friday, May 29, 2026. The Bio Medica Laboratories share price opened at ₹111.20 representing steep discount of 20.00% from issue price of ₹139.00, immediately hit lower circuit at ₹105.65 (down 23.99%).

Bio Medica Laboratories Listing Details

Bio Medica Laboratories launched its book-built IPO at ₹132-139 per share with minimum investment of 2,000 shares costing ₹2,78,000 raising ₹52.43 crore comprising fresh issue of ₹47.19 crore and offer for sale of ₹5.24 crore. The IPO received modest response with subscription of 2.26 times - retail investors at 2.92 times, NII weakly subscribed at 1.30 times, QIB at 15.94 times.

First-Day Trading Performance

Listing Price: Bio Medica Laboratories stock price opened at ₹111.20 representing steep discount of 20.00% from issue price, immediately hit lower circuit at ₹105.65 (down 23.99%), with VWAP at ₹105.90. The disastrous listing resulted in significant losses for IPO investors with turnover of ₹8.18 crore, traded volume of 7.72 lakh shares, delivery of 100%, and market capitalisation of ₹132.85 crore.

Growth Drivers and Challenges

Growth Drivers:

FY25 Revenue Growth: Revenue jumped from ₹15.34 crore in FY24 to ₹38.33 crore in FY25 (150% growth), 8M FY26 revenue of ₹28.63 crore suggesting continued momentum.

Contract Manufacturing Model: Asset-light B2B model manufacturing injectable formulations for established pharmaceutical companies under their brand names reduces marketing and distribution costs.

Strong Margins: PAT margin of 30.35% and EBITDA margin of 47.11% with ROE of 54.41% reflecting operational efficiency in parenteral formulations.

Challenges:

Inflated FY26 Financials: Analyst warns FY26 financial data appears inflated to fetch fancy valuation, bumper jump in revenue and profit after static FY23-24 performance raises sustainability concerns.

High Leverage: Debt-to-equity ratio of 2.23 indicates significant financial leverage, increasing interest burden and financial risk.

Utilisation of IPO Proceeds

New Manufacturing Facility: Proceeds towards enhancement of existing production capabilities by setting up new manufacturing facility at existing premises in Indore.

Working Capital: For meeting working capital requirements supporting contract manufacturing operations.

General Corporate Purposes: Residual amounts for general corporate purposes.

Financial Performance

Revenue: ₹28.63 crore for 8 months ended November 2025, ₹38.33 crore for FY25, growth from ₹15.34 crore in FY24 and ₹16.25 crore in FY23.

Net Profit: ₹8.66 crore for 8 months FY26, ₹9.50 crore in FY25 (up from ₹2.50 crore in FY24 and ₹0.33 crore in FY23). Investors tracking Bio Medica Laboratories share price should note analyst concerns that bumper FY26 financials raise eyebrows over sustainability given static performance in prior years, aggressive pricing, and highly competitive contract pharma segment making this a disappointing listing with 24% loss for IPO investors.